Cargando…

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion

background: IDH mutant astrocytoma has good prognosis compared with IDH wildtype one. In IDH mutant astrocytoma, However, patients with CDKN2A/B homozygous deletion (HD) are worse prognosis than non CDKN2A/B HD. Here we analyzed the prognosis of glioma patients identified with CDKN2A/B HD in our hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanagisawa, Shunsuke, Satomi, Kaishi, Miyakita, Yasuji, Ohno, Makoto, Takahashi, Masamichi, Tamura, Yukie, Kawachi, Daisuke, Kikuchi, Miyu, Kitahara, Mai, Matushita, Yuko, Yoshida, Akihiko, Ichimura, Koichi, Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648235/
http://dx.doi.org/10.1093/noajnl/vdab159.064
_version_ 1784610763733729280
author Yanagisawa, Shunsuke
Satomi, Kaishi
Miyakita, Yasuji
Ohno, Makoto
Takahashi, Masamichi
Tamura, Yukie
Kawachi, Daisuke
Kikuchi, Miyu
Kitahara, Mai
Matushita, Yuko
Yoshida, Akihiko
Ichimura, Koichi
Narita, Yoshitaka
author_facet Yanagisawa, Shunsuke
Satomi, Kaishi
Miyakita, Yasuji
Ohno, Makoto
Takahashi, Masamichi
Tamura, Yukie
Kawachi, Daisuke
Kikuchi, Miyu
Kitahara, Mai
Matushita, Yuko
Yoshida, Akihiko
Ichimura, Koichi
Narita, Yoshitaka
author_sort Yanagisawa, Shunsuke
collection PubMed
description background: IDH mutant astrocytoma has good prognosis compared with IDH wildtype one. In IDH mutant astrocytoma, However, patients with CDKN2A/B homozygous deletion (HD) are worse prognosis than non CDKN2A/B HD. Here we analyzed the prognosis of glioma patients identified with CDKN2A/B HD in our hospital. method: There were 62 cases, and female was 26. Mean age of all cases was 41.2 and median age was 38. In IDH gene status, R132H was 59 cases (95.2%), R172K 2 (3.2%) and R132S 1 (1.6%). All 62 cases were TERT wildtype. CDKN2A/B HD were 12 cases (19.4%). In log-rank test, the group of CDKN2A/B HD was poor prognosis than non HD. In astrocytoma grade 3, CDKN2A/B HD had significantly poor prognosis (p=0.002). In Cox proportional hazard model analysis, CDKN2A/B HD was effective predictive prognostic factor as well as age and grading (p=0.03). discussion/conclusion: We showed that CDKN2A/B HD was good predictive prognostic factor in IDH mutant astrocytoma.
format Online
Article
Text
id pubmed-8648235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86482352021-12-07 MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion Yanagisawa, Shunsuke Satomi, Kaishi Miyakita, Yasuji Ohno, Makoto Takahashi, Masamichi Tamura, Yukie Kawachi, Daisuke Kikuchi, Miyu Kitahara, Mai Matushita, Yuko Yoshida, Akihiko Ichimura, Koichi Narita, Yoshitaka Neurooncol Adv Supplement Abstracts background: IDH mutant astrocytoma has good prognosis compared with IDH wildtype one. In IDH mutant astrocytoma, However, patients with CDKN2A/B homozygous deletion (HD) are worse prognosis than non CDKN2A/B HD. Here we analyzed the prognosis of glioma patients identified with CDKN2A/B HD in our hospital. method: There were 62 cases, and female was 26. Mean age of all cases was 41.2 and median age was 38. In IDH gene status, R132H was 59 cases (95.2%), R172K 2 (3.2%) and R132S 1 (1.6%). All 62 cases were TERT wildtype. CDKN2A/B HD were 12 cases (19.4%). In log-rank test, the group of CDKN2A/B HD was poor prognosis than non HD. In astrocytoma grade 3, CDKN2A/B HD had significantly poor prognosis (p=0.002). In Cox proportional hazard model analysis, CDKN2A/B HD was effective predictive prognostic factor as well as age and grading (p=0.03). discussion/conclusion: We showed that CDKN2A/B HD was good predictive prognostic factor in IDH mutant astrocytoma. Oxford University Press 2021-12-06 /pmc/articles/PMC8648235/ http://dx.doi.org/10.1093/noajnl/vdab159.064 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Yanagisawa, Shunsuke
Satomi, Kaishi
Miyakita, Yasuji
Ohno, Makoto
Takahashi, Masamichi
Tamura, Yukie
Kawachi, Daisuke
Kikuchi, Miyu
Kitahara, Mai
Matushita, Yuko
Yoshida, Akihiko
Ichimura, Koichi
Narita, Yoshitaka
MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
title MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
title_full MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
title_fullStr MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
title_full_unstemmed MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
title_short MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
title_sort mpc-10 prognostic analysis in idh mutant astrocytoma patient with cdkn2a/b homozygous deletion
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648235/
http://dx.doi.org/10.1093/noajnl/vdab159.064
work_keys_str_mv AT yanagisawashunsuke mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT satomikaishi mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT miyakitayasuji mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT ohnomakoto mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT takahashimasamichi mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT tamurayukie mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT kawachidaisuke mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT kikuchimiyu mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT kitaharamai mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT matushitayuko mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT yoshidaakihiko mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT ichimurakoichi mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion
AT naritayoshitaka mpc10prognosticanalysisinidhmutantastrocytomapatientwithcdkn2abhomozygousdeletion